Biomarkers for Prediction of Gestational Diabetes Mellitus

A special issue of Reproductive Medicine (ISSN 2673-3897).

Deadline for manuscript submissions: closed (31 July 2022) | Viewed by 3923

Special Issue Editors


E-Mail Website
Guest Editor
TeleMarpe Ltd., 41 Beit El St., Tel Aviv 6908742, Israel
Interests: prenatal diagnosis; pregnancy; placenta; biochemical and biophysical markers of pregnancy complications; placental protein 13 (PP13); pro- and antiangiogenic markers of preeclampsia; preeclampsia; biophysical markers of pregnancy complications; fetal growth restriction; preterm delivery; gestational diabetes (GDM); gene polymorphisms; risk assessment of pregnancy complications in twin pregnancy; aspirin; PP13 and other drugs for fighting preeclampsia; prevention and treatment of pregnancy complications; fetal cell free DNA in maternal blood; screening and risk assessment algorithms; microbiome in health and diseases; obesity in pregnancy and other life complications; women’s health

E-Mail Website
Guest Editor
Department of Maternal Fetal Medicine, Helen Schnieder Hospital for Women, Rabin Medical Center, Jabotinsky St 39, Petah Tikva 4941492, Israel
Interests: obstetrics and gynecology; fetal growth restriction; obstetric delivery; prenatal diagnosis and screening; gestational diabetes—diagnosis, treatment and prevention; diabetes hypertension; diabetes mellitus; gynecological surgery; reproductive medicine; maternal and fetal medicine; COVID-19 in pregnant women; anti-COVID-19 vaccination of pregnant women; microRNA markers in pregnancy; microbiome and metabolites in pregnancy; pre- and postpregnancy clinics

E-Mail Website
Guest Editor
Department of Hepatology and Gastroenterology, Aarhus University Hospital99 Palle Juul-Jensens Boulevard, 8200 Aarhus N, Denmark
Interests: internal medicine (general medicine); gastroenterology; hepatology; liver transplants; liver diseases and complications in pregnancy; liver derived biomarkers; CD163; gene-based drug therapy

E-Mail Website
Guest Editor
Department of Clinical Genetics and Centre for Fetal Diagnostics, Aarhus University Hospital, 99 Palle Juul-Jensens Boulevard, 8200 Aarhus N, Denmark
Interests: prenatal diagnosis; trisomies and atypical chromosomes; medical genetics; molecular methods of gene-based disorders; circulating fetal cells in maternal blood; cell-free fetal DNA; genetic screening; karyotyping; whole genome sequencing; whole exome sequencing; gene markers; polymorphisms

Special Issue Information

Dear Colleagues,

Gestational diabetes mellitus (GDM), the most common metabolic disorder in pregnancy, is associated with glucose intolerance in the 2nd and 3rd trimesters, leading to hyperglycemia. Driven by maternal obesity, physical inactivity, and increased maternal age, GDM increases the risk of severe complications, including birth trauma, shoulder dystocia, macrosomia, neonatal hypoglycemia and hyperbilirubinemia, and stillbirth. GDM patients have a significantly increased lifetime risk for type 2 diabetes, while their offspring are more likely to develop type 2 diabetes, obesity, metabolic, and cardiovascular disease later in life. In the past decade, early effective methods in GDM prevention were developed to decrease its prevalence and severity. We focus on GDM biomarkers for early prediction to improve treatment and prevention. Such markers could be proteins, microRNAs, microbiome, and metabolites, providing accurate GDM5 screening, whether with known underlying pathological mechanisms or with proven prediction of GDM progression, potentially linked to placental trophoblasts.

Dr. Hamutal Meiri
Prof. Dr. Eran Hadar
Prof. Dr. Henning Gronbaek
Prof. Dr. Ida Vogel
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Reproductive Medicine is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gestational diabetes mellitus (GDM)
  • maternal serum biomarkers
  • prenatal diagnosis of GDM
  • prediction of GDM
  • prevention of GDM
  • first trimester
  • obesity
  • hyperglycemia
  • singleton and twin pregnancy
  • mathematical models and risk assessment

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 541 KiB  
Review
Early Identification of the Maternal, Placental and Fetal Dialog in Gestational Diabetes and Its Prevention
by Amir Naeh, Esther Maor-Sagie, Mordechai Hallak and Rinat Gabbay-Benziv
Reprod. Med. 2022, 3(1), 1-14; https://doi.org/10.3390/reprodmed3010001 - 23 Dec 2021
Cited by 3 | Viewed by 3241
Abstract
Gestational diabetes mellitus (GDM) complicates between 5 and 12% of pregnancies, with associated maternal, fetal, and neonatal complications. The ideal screening and diagnostic criteria to diagnose and treat GDM have not been established and, currently, diagnostic use with an oral glucose tolerance test [...] Read more.
Gestational diabetes mellitus (GDM) complicates between 5 and 12% of pregnancies, with associated maternal, fetal, and neonatal complications. The ideal screening and diagnostic criteria to diagnose and treat GDM have not been established and, currently, diagnostic use with an oral glucose tolerance test occurs late in pregnancy and produces poor reproducibility. Therefore, in recent years, significant research has been undertaken to identify a first-trimester biomarker that can predict GDM later in pregnancy, enable early intervention, and reduce GDM-related adverse pregnancy outcomes. Possible biomarkers include glycemic markers (fasting glucose and hemoglobin A1c), adipocyte-derived markers (adiponectin and leptin), pregnancy-related markers (pregnancy-associated plasma protein-A and the placental growth factor), inflammatory markers (C-reactive protein and tumor necrosis factor-α), insulin resistance markers (sex hormone-binding globulin), and others. This review summarizes current data on first-trimester biomarkers, the advantages, and the limitations. Large multi-ethnic clinical trials and cost-effectiveness analyses are needed not only to build effective prediction models but also to validate their clinical use. Full article
(This article belongs to the Special Issue Biomarkers for Prediction of Gestational Diabetes Mellitus)
Show Figures

Figure 1

Back to TopTop